Business context and reporting period
IRADIMED Corporation’s unaudited Form 10-Q covers the quarter and six months ended June 30, 2014. The company develops, manufactures and sells MRI-compatible IV infusion pump systems, accessories, disposable tubing sets and related services, primarily to hospitals and acute-care facilities. Its revenue and profitability depend heavily on its MRidium pump systems.
Financial performance and liquidity
| Metric | Three months ended June 30, 2014 | Six months ended June 30, 2014 |
|---|---|---|
| Revenue | $4.70 million; up 69.4% year over year | $8.26 million; up 52.8% |
| Gross profit / margin | $3.83 million / 81.5%, versus 72.3% | $6.73 million / 81.5%, versus 77.1% |
| Operating income / margin | $1.61 million / 34.3%, versus $0.78 million / 28.1% | $2.43 million / 29.5%, versus $1.71 million / 31.6% |
| Net income | $1.02 million, versus $0.56 million; diluted EPS $0.11 versus $0.07 | $1.54 million, versus $1.20 million; diluted EPS $0.17 versus $0.14 |
| Operating cash flow | $2.25 million for the six months, versus $0.52 million |
Q2 gross-margin improvement reflected higher domestic sales and better labor and equipment utilization. Six-month operating expenses rose to $4.30 million from $2.46 million, with higher general and administrative costs a principal increase. The six-month effective tax rate rose to 37.0% from 30.4%, contributing to a lower net margin despite higher earnings.
At June 30, cash and cash equivalents were $4.26 million, working capital was approximately $6.0 million, and stockholders’ equity was $7.30 million. Total liabilities were $2.64 million; the filing reports no outstanding borrowings at period-end. The $6,333 officer note was repaid in March. Six-month investing cash use was $239,000 and financing cash use was $210,000, including IPO costs. In July, the company completed its IPO of 2,318,400 shares at $6.25 per share, generating approximately $12.5 million in net proceeds; preferred shares converted to common stock at closing.
Changes, outlook and material risks
- Domestic revenue drove growth: Q2 U.S. sales rose 134.0% to $4.22 million, while international sales fell 50.3% to $0.48 million. For the first half, U.S. sales rose 72.3% to $6.67 million and international sales were approximately flat at $1.59 million.
- Pump sales increased to 146 in Q2 from 108 and to 292 in the first half from 199. Management attributed higher average selling prices to a greater domestic sales mix.
- Management expects 2014 revenue to increase, citing expansion of the U.S. sales force and efforts to convert users of a former competitor’s pumps. It also expects higher operating expenses from added headcount, capital expenditures, the new facility and public-company costs. No numerical full-year guidance is provided.
- The company moved manufacturing and headquarters operations to a new 27,000-square-foot leased facility in July. The landlord, Susi, LLC, is controlled by the CEO; base rent is $32,583 monthly, subject to annual CPI adjustment.
- The FDA’s April 2014 inspection resulted in a Form 483 with eight observations, mainly concerning software design and documentation, testing, labeling and complaint handling. The company submitted proposed corrective and preventive actions; further regulatory action remains a risk if the FDA does not accept or finds the actions inadequate.
- Major business risks include dependence on a single pump product, reliance on single-source suppliers (including the ultrasonic motor supplier), a single manufacturing facility, and customer concentration: one customer represented 29.2% of gross receivables at June 30. One major GPO contract was due to expire in 2014 unless renewed.
- Radimed is pursuing German and EU trademark claims against the company and its founder, seeking to restrict use of the IRADIMED name and unspecified damages. The company has not accrued a loss because it considers a loss not probable or estimable.
- Other unusual items include prior voluntary recalls: an infusion-set recall was declared terminated by the FDA in 2013, and a separate 2013 recall involved pumps with a drug-library issue. The company also liquidated its mutual-fund investments after June 30 and terminated its uncommitted $100,000 credit facility.
Important facts for investors to verify
- Progress and FDA response regarding the eight Form 483 observations, including implementation of corrective actions.
- Whether the 2014 GPO contract was renewed and whether domestic growth can offset weaker quarterly international sales.
- Customer receivable concentration, supplier continuity and capacity to scale production at the new facility.
- Status and potential financial or commercial consequences of the Radimed trademark litigation.
- Post-IPO cash position and the pace of operating-expense growth against management’s non-quantified revenue outlook.
- The filing states that interim results are unaudited and are not necessarily indicative of full-year results.